巴西慢性乙型肝炎抗病毒药物成本效果分析数据

数据集获取（Figshare）

• 源站标题：Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis
• DOI：10.6084/m9.figshare.14292045.v1
• 发布日期：2021-03-24
• 文件数：5 个
• 文件总体积：546.56 KB
• 源站页面：https://scielo.figshare.com/articles/dataset/Incorporated_antivirals_for_chronic_hepatitis_B_in_Brazil_a_cost-effectiveness_analysis/14292045

命令行下载

curl -L -o "0034-8910-rsp-47-04-0769-gf01-en.jpg" "https://ndownloader.figshare.com/files/27184343"
curl -L -o "Table_1.xls" "https://ndownloader.figshare.com/files/27184345"
curl -L -o "Table_2.xls" "https://ndownloader.figshare.com/files/27184347"
curl -L -o "Table_3.xls" "https://ndownloader.figshare.com/files/27184349"
curl -L -o "Table_4.xls" "https://ndownloader.figshare.com/files/27184351"

文件清单

• 0034-8910-rsp-47-04-0769-gf01-en.jpg（519.93 KB）
• Table_1.xls（5.63 KB）
• Table_2.xls（9.73 KB）
• Table_3.xls（5.63 KB）
• Table_4.xls（5.63 KB）

文件总体积 546.56 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

OBJECTIVE To evaluate the cost-effectiveness of different drug therapies for chronic hepatitis B in adult patients. METHODS Using a Markov model, a hypothetical cohort of 40 years for HBeAg-positive or HBeAg-negative patients was constructed. Adefovir, entecavir, tenofovir and lamivudine (with rescue therapy in cases of viral resistance) were compared for treating adult patients with chronic hepatitis B undergoing treatment for the first time, with high levels of alanine aminotransferase, no evidence of cirrhosis and without HIV co-infection. Values for cost and effect were obtained from the literature, and expressed in effect on life years (LY). A discount rate of 5% was applied. Univariate sensitivity analysis was conducted to assess model uncertainties. RESULTS Initial treatment with entecavir or tenofovir showed better clinical outcomes. The lowest cost-effectiveness ratio was for entecavir in HBeAg-positive patients (R$ 4,010.84/LY) and lamivudine for HBeAg-negative patients (R$ 6,205.08/LY). For HBeAg-negative patients, the incremental cost-effectiveness ratio of entecavir (R$ 14,101.05/LY) is below the threshold recommended by the World Health Organization. Sensitivity analysis showed that variation in the cost of drugs may make tenofovir a cost-effective alternative for both HBeAg-positive and HBeAg-negative patients. CONCLUSIONS Entecavir is the recommended alternative to start treating patients with chronic hepatitis B in Brazil. However, if there is a reduction in the cost of tenofovir, it can become a cost-effective alternative.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.14292045.v1（source: https://scielo.figshare.com/articles/dataset/Incorporated_antivirals_for_chronic_hepatitis_B_in_Brazil_a_cost-effectiveness_analysis/14292045）。